
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/10196/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:06:49 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--10196 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--10196 block--content--website-notice-block block--content--website-notice-block--10196 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--10196 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--10196 block--content--system-main-block block--content--system-main-block--10196 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--10196 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001558370-24-008556.rtf%3b%20filename_%3dUTF-8%27%270001558370-24-008556.rtf" type="application/rtf" title="0001558370-24-008556.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001558370-24-008556.pdf%3b%20filename_%3dUTF-8%27%270001558370-24-008556.pdf" type="application/pdf" title="0001558370-24-008556.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001558370-24-008556.xls%3b%20filename_%3dUTF-8%27%270001558370-24-008556.xls" type="application/vnd.ms-excel" title="0001558370-24-008556.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001558370-24-008556.html" type="application/octet-stream" title="0001558370-24-008556-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/22/2024 11:56:25 AM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: 937c378a-3947-44e6-8cf7-f22132489c4c -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srrk="http://scholarrock.com/20240517" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="../../../www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityCentralIndexKey" id="Tc_9qvJKEnbW0aLfblriT_gHg_1_1">0001727196</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:AmendmentFlag" id="Tc_Ne4e6iMKQkGYBIctfF8cRw_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20240517.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-17</xbrli:startDate><xbrli:endDate>2024-05-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d94ac805_c8b4_4518_9599_5f2a7041dd00"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:DocumentType" id="Narr_i7u-RR-m80q_Zd0hUVnrhw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Report (Date of earliest event Reported): <ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_pxMeEILN8Ue0nRv2ePUKBA">May&#160;17, 2024</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityRegistrantName" id="Narr_zNB7O8eJFU6vG2_BT_IeIA"><b style="font-weight:bold;">Scholar Rock Holding Corporation</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7714d3ad_1e31_4ade_b6a6_d952b317cb59"></a><a id="Tc_nbhADfeapEGSMK3zXV8y2w_2_0"></a><a id="Tc_b-J5OgbqcUGbbShDHrYhkg_2_2"></a><a id="Tc_xLZKJ_a-Skakzh9Q4glJkg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_tEeQfP1y6Um7bo45uAj9UA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityFileNumber" id="Tc_YeCJ0Q5x60Gb9k7zOVEnKw_1_2"><b style="font-weight:bold;">001-38501</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityTaxIdentificationNumber" id="Tc_Ou9s1JYSSE6xjBskFl7m5A_1_4"><b style="font-weight:bold;">82-3750435</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:34.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of<br/>Incorporation)</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification Number)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityAddressAddressLine1" id="Narr_hXIKDkJiJ0id6-D-J5BbSw"><b style="font-weight:bold;">301 Binney Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityAddressAddressLine2" id="Narr_Vjm5ex9w-kCeeql2cPIzxg"><b style="font-weight:bold;">3rd Floor</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityAddressCityOrTown" id="Narr_lLovqGlBL0eLeWG_3Jt73w"><b style="font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityAddressStateOrProvince" id="Narr__AqzOedPm0yUH-aQvLwIJw"><b style="font-weight:bold;">MA</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:EntityAddressPostalZipCode" id="Narr_7jjeUyYW7EyLZrqIlDcSPg"><b style="font-weight:bold;">02142</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:CityAreaCode" id="Narr_dnwsScdBhkGFX4pNiD7iZw"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:LocalPhoneNumber" id="Narr_Bml5PibizEK6l1QPA1ZK_g"><b style="font-weight:bold;">259-3860</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f61dccba_038d_4a73_b15e_bfe8fb502b5f"></a><a id="Tc_eOBMpHCQ-U6XB7SRL-zSyQ_1_1"></a><a id="Tc_ltCwD-2wgkiFWax_U7JBIg_2_1"></a><a id="Tc_imDFFKbasEOI679tI5vfFA_3_1"></a><a id="Tc_BKRHiXf7_Ea8xrNQTloEYA_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.99%;"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_Q9rNBI37aUu34LwvlIuQpA_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_VciNFZaOXES6FPGbLfpp0A_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_AhGmLCc3W0ap_RzpM1MIWw_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_q8rKXfHb_kShXbtClUhKtQ_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_37778da4_9d78_44d3_8282_ebcf5d73a0f9"></a><a id="Tc_e1P-VIQUiE2fFpLfmqZxlg_1_0"></a><a id="Tc_-t7_f2yg_EGWXAO5pDzkHw_1_2"></a><a id="Tc_m-3rQM1PdUeANkMOnn37yQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.15%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.18%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.65%;margin:0pt;padding:1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:24.18%;border-bottom:1px solid #000000;margin:0pt;padding:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.65%;border-bottom:1px solid #000000;margin:0pt;padding:1pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:middle;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:1pt 1pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:Security12bTitle" id="Tc_UVER0SUUo0yDBqOXpjM_PA_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.18%;border-top:1px solid #000000;margin:0pt;padding:1pt 1pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" name="dei:TradingSymbol" id="Tc_EKl_a9VrC0aHofWfKqFywg_2_2">SRRK</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:1pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:36.65%;border-top:1px solid #000000;margin:0pt;padding:1pt 1pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_VboDUgCSTkaNrnVJLR88Zw_2_4">Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company <ix:nonNumeric contextRef="Duration_5_17_2024_To_5_17_2024_BDZ4HU6LN0KGbCBwNQmVpA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Ne5e6iEsy02Di4fDSc_ZRg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_339ebc9f_6b1d_4f85_9d7c_823e397634f1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><b style="font-weight:bold;">Item 1.01. Entry Into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">Amendment  No. 4 to  Loan and Security Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><a id="_Hlk166672115"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 15.75pt 0pt 0pt;">On May 17, 2024 (the &#8220;Effective Date&#8221;), Scholar Rock Holding Corporation (the &#8220;Company&#8221; or &#8220;we&#8221;) and Scholar Rock, Inc., a wholly-owned subsidiary of the Company (&#8220;Scholar Rock&#8221; and collectively with the Company, the &#8220;Borrower&#8221;), entered into the Fourth Amendment (&#8220;Loan Amendment No. 4&#8221;) to the Loan and Security Agreement, dated October 16, 2020, by and with Oxford Finance LLC and Silicon Valley Bank (each, a &#8220;Lender&#8221; and collectively, the &#8220;Lenders&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Loan Agreement, we previously received $50 million in loan proceeds under the Loan Agreement. Pursuant to Loan Amendment No. 4, we and the Lenders agreed to amend the milestones required to access an additional tranche of $25.0 million that is available to us under the Loan Agreement. The fourth tranche is available at our discretion through December 2024, upon achievement of certain clinical and business milestones. Loan Amendment No. 4 also extended the interest-only payment period for an additional six months through May 2025, with principal payments to commence in June 2025, or for an additional six months through November 2025 upon achievement of certain business performance milestones, with principal payments to commence in December 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The foregoing description of Loan Amendment No. 4 does not purport to be complete and is qualified in its entirety by reference to Loan Amendment No. 4, which we intend to file as an exhibit to our Form 10-Q for the fiscal quarter ending June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><b style="font-weight:bold;">Item 7.01. Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">On May 22, 2024, the Company will hold its previously announced &#8220;Investor Day&#8221; event beginning at 8:30 a.m. ET. During the event, representatives of the Company will, among other things, provide a business update, including the initiation of the Phase 2 EMBRAZE trial of apitegromab in obesity and provide new preclinical data for SRK-439 in obesity. A copy of the press release relating to the Investor Day event is attached hereto as Exhibit 99.1 and a copy of the presentation slides to be used by the Company during the Investor Day event and webcast is attached hereto as Exhibit 99.2. A live webcast of the Investor Day event may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at http://investors.scholarrock.com. A recording of the webcast will also be available on the Company&#8217;s website after the event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">The information in this report furnished pursuant to Item 7.01 and Exhibits 99.1 and 99.2 shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibits 99.1 and 99.2 of this report.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><b style="font-weight:bold;">Item 8.01. Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 2 EMBRAZE Proof-of-Concept Trial</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="white-space:pre-wrap;">On May 22, 2024, the Company announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist (GLP-1 RA).  The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">EMBRAZE is a randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept trial evaluating the efficacy, safety and pharmacokinetics of apitegromab in adults with a body mass index (BMI) of &gt;27 (overweight) or a BMI of &gt;30 (obese) and taking a GLP-1 RA (tirzepatide or semaglutide). The target enrollment of EMBRAZE is 100 subjects aged 18-65 who are overweight or obese without diabetes. As part of the study design, the treatment period is 24 weeks, and all subjects will receive a GLP-1 RA. In addition, all subjects will be randomized 1:1 to receive either apitegromab or placebo by intravenous (IV) infusion every four weeks during the 24-week treatment period. The primary endpoint is change from baseline at Week 24 in lean mass assessed by dual-energy X-ray absorptiometry. Secondary endpoints </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">include additional weight loss measures, safety and tolerability, and pharmacokinetic outcomes. Exploratory endpoints at Weeks 24 and 32 include cardiometabolic parameters (e.g., HbA1c), body composition, and physical function. Primary data from EMBRAZE are expected in mid-2025 and will inform the Company&#8217;s development of SRK-439 towards anticipated IND filing in 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SRK-439</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">On May 22, 2024, the Company also announced new preclinical data from a head-to-head comparison of SRK-439 and an anti-activin receptor II (anti-ActRII) antibody which demonstrate SRK-439&#8217;s potential as best in class in preserving lean mass in patients on GLP-1 RAs. For the head-to-head preclinical research study, the Company generated and tested an anti-ActRII antibody (a murine equivalent of bimagrumab) along with a murine equivalent of SRK-439 in a weight-stable diet-induced obesity (DIO) mouse model. Mice were given either semaglutide (0.04mg/kg, daily) with an IgG control antibody (weekly, 20mg/kg) or semaglutide (0.04mg/kg, daily) in combination with weekly injections of either SRK-439 (0.3-10mg/kg) or anti-ActRII (0.3-20mg/kg). Quantitative nuclear magnetic resonance (qNMR) was then used to analyze change in lean mass after four weeks of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">Lean mass differences were significant in all doses of SRK-439 tested, supporting the hypothesis that SRK-439 could be an important therapy to aid in lean mass preservation and is suitable for subcutaneous dosing in a population of adults with obesity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">SRK-439 attenuated the GLP-1 RA-driven lean mass loss in combination with semaglutide at a dose as low as 0.3 mg/kg (8.3% lean mass loss from baseline) and with maximal effects observed at all doses over 1 mg/kg (4.2% lean mass loss from baseline at 10mg/kg), as compared to an IgG control + semaglutide (14.1% lean mass loss from baseline). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">Superiority to anti-ActRII antibody was shown in all equivalent doses tested:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3 mg/kg: -4.7% SRK-439 vs. -12.0% for anti-ActRII</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1 mg/kg: -5.0% SRK-439 vs. -12.6% for anti-ActRII</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:0.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.3 mg/kg: -8.3% SRK-439 vs. -15.4% for anti-ActRII.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">Equivalent lean mass preservation was seen at the highest dose tested for both drugs; 10 mg/kg SRK-439 (-4.2%) and 20 mg/kg anti-ActRII (-4.3%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d) Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:92.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:92.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:7.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="#srrk-20240517xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release issued by the Company on May 22, 2024, furnished hereto.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;width:92.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="#srrk-20240517xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investor Day Presentation, furnished hereto.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:0.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:92.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_d57e0665_6f8c_4d98_ad47_1cf4fd1a1898"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Scholar Rock Holding Corporation</b></p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 22, 2024</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Junlin Ho</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Junlin Ho</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Counsel&#160;and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body>
<!-- Mirrored from investors.scholarrock.com/node/10196/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:06:49 GMT -->
</html>
</XBRL>
<div><a name="srrk-20240517xex99d1.htm"></a></div><!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 5/22/2024 11:56:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:center;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-decoration-line:line-through;text-decoration-style:solid;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Phase 2 EMBRAZE proof-of-concept trial </i><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">designed to assess apitegromab&#39;s ability to safely preserve lean muscle mass in individuals on GLP-1 receptor agonist therapy for obesity</i></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;line-height:1.28;margin-bottom:8pt;margin-left:0pt;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:center;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">New preclinical head-to-head comparison shows that SRK-439 is more potent than an anti-ActRII antibody in maintaining lean mass in diet-induced obesity (DIO) mice; lean mass loss with SRK-439, 1mg/kg dose was equivalent to anti-ActRII antibody, 20mg/kg dose </i></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;line-height:1.28;margin-bottom:8pt;margin-left:0pt;text-decoration-line:line-through;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:center;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;white-space:pre-wrap;">Company hosting Investor Event today in New York City focusing on its selective latent myostatin inhibition programs in Spinal Muscular Atrophy and obesity with presentations from executive leadership and key experts  </i></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CAMBRIDGE, Mass. &#8212; May 22, 2024 &#8212; </font><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock&#160;(NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role,</font><font style="font-family:'Times New Roman','Times','serif';"> today announced the initiation of the Phase 2 EMBRAZE proof-of-concept </font><font style="font-family:'Times New Roman','Times','serif';">trial, </font><font style="font-family:'Times New Roman','Times','serif';">designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity </font><font style="font-family:'Times New Roman','Times','serif';">and on background therapy of a GLP-1 receptor agonist (GLP-1 RA). The results from this trial will inform the development of </font><font style="font-family:'Times New Roman','Times','serif';">SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company also announced n</font><font style="font-family:'Times New Roman','Times','serif';">ew preclinical data from a head-to-head comparison of SRK-439 and an anti-activin receptor II (anti-ActRII) antibody, which </font><font style="font-family:'Times New Roman','Times','serif';">demonstrate SRK-439&#8217;s potential as best in class in preserving lean mass in patients on GLP-1 RAs</font><font style="font-family:'Times New Roman','Times','serif';">. This data will be presented by Mo Qatanani, Ph.D., Chief Scientific Officer, at Scholar Rock&#8217;s Investor Event, which begins today at 8:30 a.m. ET and is being held in New York City</font><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;We are thrilled to have initiated the EMBRAZE clinical trial ahead of schedule and to share new data from our SRK-439 program, which we believe further support our hypothesis that selective latent myostatin inhibition has advantages over less selective approaches to safely and effectively maintain lean muscle mass,&#8221; said Jay Backstrom, M.D., MPH, President and Chief Executive Officer at Scholar Rock. &#8220;Selectivity is key in mitigating potential safety concerns for this patient population and we look forward to sharing additional preclinical data at the American Diabetes Association 84</font><sup style="font-family:'Times New Roman','Times','serif';font-size:8.25pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';"> Scientific Sessions in June to support the best-in-class potential of SRK-439.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">New SRK-439 Data</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For the head-to-head preclinical research study, the Company generated and tested an anti-ActRII antibody (a murine equivalent of bimagrumab), along with a murine equivalent of SRK-439 in a weight-stable diet induced obesity (DIO) mouse model. </font><font style="font-family:'Times New Roman','Times','serif';">Mice were given either semaglutide (0.04mg/kg, daily) with an IgG control antibody (weekly, 20mg/kg) or semaglutide (0.04mg/kg, daily) in combination with weekly injections of either SRK-439 (0.3-10mg/kg) or of the anti-ActRII antibody (0.3-20mg/kg). </font><font style="font-family:'Times New Roman','Times','serif';">Quantitative nuclear magnetic resonance (qNMR) was used to analyze change in lean mass after four weeks of treatment.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Lean mass differences were significant in all doses of SRK-439 tested, supporting the hypothesis that SRK-439 could be an important therapy to aid in lean mass preservation and is suitable for subcutaneous dosing in a population of adults with obesity. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Aptos';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">SRK-439 attenuated the GLP-1 RA-driven lean mass loss in combination with semaglutide at a dose as low as 0.3 mg/kg (8.3% lean mass loss from baseline).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Aptos';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Maximal effects observed at all doses over 1 mg/kg (4.2% lean mass loss from baseline at 10mg/kg), as compared to an IgG control + semaglutide (14.1% lean mass loss from baseline).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Aptos';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Superiority to anti-ActRII antibody was shown in all equivalent doses tested:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">3 mg/kg: -4.7% SRK-439 vs. -12.0% for anti-ActRII</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1 mg/kg: -5.0% SRK-439 vs. -12.6% for anti-ActRII</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">0.3 mg/kg: -8.3% SRK-439 vs. -15.4% for anti-ActRII</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Aptos';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Equivalent lean mass preservation was seen at the highest dose tested for both drugs; 10 mg/kg SRK-439 (-4.2%) and 20 mg/kg anti-ActRII (-4.3%). </font></td></tr></table><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;The data from this head-to-head comparison </font><font style="font-family:'Times New Roman','Times','serif';">show that selectively inhibiting myostatin alone is sufficient to preserve lean mass on a background of GLP-1 RA, in preclinical models. Combined with the positive data observed at low doses of SRK-439, we believe that our selective myostatin approach is the right potential solution to preserve lean muscle mass while avoiding the potential off-target effects observed in less selective programs for this indication. We view this as strong evidence that SRK-439 could have a more favorable benefit/risk profile,&#8221; s</font><font style="font-family:'Times New Roman','Times','serif';">aid Mo Qatanani, Ph.D., Chief Scientific Officer at Scholar Rock.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Phase 2 EMBRAZE Trial Design</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><a name="_Hlk167186757"></a><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock announced in January that the U.S. Food and Drug Administration cleared the Company&#8217;s Investigational New Drug (IND) application for EMBRAZE, a randomized, double-blind, placebo-controlled, </font><font style="font-family:'Times New Roman','Times','serif';">Phase 2 proof-of-concept trial evaluating the efficacy, safety and pharmacokinetics of apitegromab in adults with a body mass index (BMI) of &gt;27 (overweight) or a BMI of &gt;30 (obese) and taking a GLP-1 RA (tirzepatide or semaglutide). The target enrollment of EMBRAZE is 100 subjects aged 18-65 who are overweight or obese without diabetes. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As part of the study design, the treatment period is 24 weeks, and all subjects will receive a GLP-1 RA. In addition, all subjects will be randomized 1:1 to receive either apitegromab or placebo by intravenous (IV) infusion every four weeks during the 24-week treatment period. The primary endpoint is change from baseline at Week 24 in lean mass assessed by dual-energy X-ray absorptiometry. Secondary endpoints include additional weight loss measures, safety and tolerability, and pharmacokinetic outcomes. Exploratory endpoints at Weeks 24 and 32 include cardiometabolic parameters (e.g. HbA1c), body composition, and physical function. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Primary data from EMBRAZE are expected in mid-2025 and will inform Scholar Rock&#8217;s development of SRK-439 towards an anticipated IND filing in 2025. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The presentation from Scholar Rock&#8217;s Investor Day will be available in the </font><font style="font-family:'Times New Roman','Times','serif';">Investors and Media section</font><font style="font-family:'Times New Roman','Times','serif';"> of Scholar Rock&#8217;s website. </font><font style="font-family:'Times New Roman','Times','serif';">Live webcast of the event may be accessed by visiting the Investors &amp; Media section of the Scholar Rock website at </font><font style="font-family:'Times New Roman','Times','serif';">http://investors.scholarrock.com</font><font style="font-family:'Times New Roman','Times','serif';">. An archived replay of the webcast will be available on the Company&#8217;s website for approximately 90 days following the presentations.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About SRK-439</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">SRK-439 is a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity (i.e., no GDF11 or Activin-A binding), and is initially being developed for the treatment of cardiometabolic disorders, including obesity. Based on preclinical data, SRK-439 has the potential to support healthier weight management by preserving lean mass during weight loss. The efficacy and safety of SRK-439 have not been established and SRK-439 has not been approved for any use by the FDA or any other regulatory agency.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About Apitegromab</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate to demonstrate clinical proof-of-concept in spinal muscular atrophy (SMA). Myostatin, a member of the TGF&#946; superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">About&#160;Scholar Rock</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGF&#946;) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Availability of Other Information About Scholar Rock</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This press release contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and prospects, including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab and its preclinical programs, including SRK-439, and indication selection and development timing, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management&#39;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2a clinical trial of apitegromab, or its preclinical data with respect to SRK-439, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA or the Phase 2a EMBRAZE clinical trial; Scholar Rock&#8217;s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property; Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials; and Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives; as well as those risks more fully discussed in the section entitled &quot;Risk Factors&quot; in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Scholar Rock:</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investors </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Rushmie Nofsinger</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">rnofsinger@scholarrock.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">ir@scholarrock.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">857-259-5573</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Media </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Molly MacLeod </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Scholar Rock </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">mm</font><font style="font-family:'Times New Roman','Times','serif';">acleod@scholarrock.com </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">media@scholarrock.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">802-579-5995 </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
<div><a name="srrk-20240517xex99d2.htm"></a></div><html><head></head><body link=blue lang="EN-US"><div><div align="center"><div align="center"><div style="position:absolute; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;">Exhibit 99.2</div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g001.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Investor Day
May 22, 2024
1</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g002.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Welcome
Rushmie Nofsinger
Vice President
Investor Relations &amp; Corporate Affairs
2</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g003.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Forward-Looking Statements
Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively,
&#x201C;Scholar Rock&#x201D;), including without limitation, Scholar Rock&#x2019;s expectations regarding its strategy, its product candidate selection and development timing, including timing for the
initiation of and reporting results from its preclinical studies and clinical trials for SRK-439, apitegromab, SRK-181, and other product candidates and indication selection and
development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and
the potential of its product candidates and proprietary platform. The use of words such as &#x201C;may,&#x201D; &#x201C;could,&#x201D; &#x201C;might,&#x201D; &#x201C;will,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; &#x201C;plan,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D;
&#x201C;estimate,&#x201D; &#x201C;project,&#x201D; &#x201C;intend,&#x201D; &#x201C;future,&#x201D; &#x201C;potential,&#x201D; or &#x201C;continue,&#x201D; and other similar expressions are intended to identify such forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based on management's current expectations of
future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 trial of apitegromab
or Part A or Part B of the Phase 1 trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of
the same product candidate, including the Phase 3 clinical trial of apitegromab in SMA and Part B of the Phase 1 clinical trial of SRK-181, respectively, Scholar Rock&#x2019;s ability to
provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#x2019;s
nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing
products for similar uses, Scholar Rock&#x2019;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#x2019;s current and potential future collaborations,
Scholar Rock&#x2019;s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock&#x2019;s
ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new
business initiatives, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#x2019;s Form 10-K for the year ended December 31, 2023, and
Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#x2019;s
subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock&#x2019;s views only as of today and should not be relied upon
as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this
information unless required by law.
This presentation may also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our
industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions,
and estimates of our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk.
Apitegromab and SRK-181 are investigational drug candidates under evaluation. Apitegromab, SRK-181, and SRK-439 have not been approved for any use by the FDA or any
other regulatory agency and the safety and efficacy of apitegromab, SRK-181 and SRK-439 have not been established.</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g004.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Company Speakers
4
Jay Backstrom, M.D., MPH
President &amp; Chief
Executive Officer
Jing Marantz, M.D., Ph.D.
Chief Medical Officer
Tracey Sacco
Chief Commercial Officer
Mo Qatanani, Ph.D.
Chief Scientific Officer</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g005.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Expert Speakers
5
Diana Castro, M.D.
Founder of Neurology &amp; Neuromuscular Care Center
and Neurology Rare Disease Center
Former Associate Professor of Pediatrics, Neurology
and Neurotherapeutics, University of Texas
Southwestern, Director of the Neuromuscular Program
&amp; Fellowship and Director of the Pediatric Muscular
Dystrophy Association Clinic at Children&#x2019;s Health
Ania Jastreboff, M.D., Ph.D.
Associate Professor of Medicine (Endocrinology), Yale School
of Medicine
Director, Yale Obesity Research Center (Y-Weight)
Co-Director, Yale Center for Weight Management
Member of Board of Directors for the American Board of
Obesity Medicine</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g006.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Today&#x2019;s Agenda
6
Topic Speaker
&#xF084; Welcome Rushmie Nofsinger, VP of IR &amp; Corporate Affairs
&#xF084; Vision &amp; Strategic Overview Jay Backstrom, President &amp; Chief Executive Officer
&#xF084; SMA: The Patient Journey Diana Castro, M.D., Neurology &amp; Neuromuscular Care Center
and Neurology Rare Disease Center
&#xF084; Apitegromab: Development Program Jing Marantz, Chief Medical Officer
&#xF084; Apitegromab: Commercial Readiness Tracey Sacco, Chief Commercial Officer
Q&amp;A
10-minute Break
&#xF084; Obesity: Muscle Matters Ania Jastreboff, M.D., Ph.D., Yale School of Medicine
&#xF084; SRK-439: Differentiated Approach Mo Qatanani, Chief Scientific Officer
&#xF084; Cardiometabolic Development Program Jing Marantz, Chief Medical Officer
Q&amp;A
&#xF084; Closing Remarks Jay Backstrom, President &amp; Chief Executive Officer
8:30 &#x2013; 12:00</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g007.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Building a Fully
Integrated Biopharma
Company
Jay Backstrom
President &amp; Chief Executive Officer</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g008.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">8
TGF
&#x3B2;=Transforming growth factor
-beta.
OUR MISSION
To discover, develop, and deliver life
-changing
therapies by harnessing cutting
-edge science
to create new possibilities for people living with
serious diseases
We are a global leader in
harnessing the life
-changing
potential of TGF
&#x3B2; biology</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g009.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Selectivity is
the Key
The hallmark of our
differentiated platform is
unparalleled selectivity
1
Large Unmet Needs
SMA and obesity represent high
value markets offering significant
potential revenue opportunities
2
Positioned
for Success
Experienced team executing
on strategy and goals
3
Advancing Our Journey Towards Commercialization
9
W H A T Y O U W I L L H E A R T O D A Y
Next 12 &#x2013; 24 months of execution is
expected to be transformative for our
company</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g010.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Evolving into a Fully Integrated Biopharma Company
A G E N D A
Building a muscle-targeted franchise
The road ahead &#x2013; value drivers
Leveraging our proprietary platform
10</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g011.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Scholar Rock&#x2019;s Target
Latent Growth Factor
Traditional Target
&#x201C;Mature&#x201D; Active Growth Factor
Scholar Rock Has Succeeded Where Others Have Failed
11
Targeting the &#x2018;cage&#x2019; before
growth factor is released allows
for exquisite selectivity
Has been challenging to target
because of high homology
across super-family
RIGHT
TIME
Latent
Form
RIGHT
TARGET
Validated
Biology
S E L E C T I V I T Y D R I V E S S U C C E S S</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g012.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Growing Pipeline Across High Value Therapeutic Areas
12 *Utilized data from previously completed Ph 1 study in healthy volunteers and initiate a Ph 2 POC trial in 2024.
LTBP1=Latent transforming growth factor beta binding protein 1; LTBP3=Latent transforming growth factor beta binding protein 3; POC=Proof of concept; RGMc=Repulsive guidance molecule C;
TGF&#x3B2;-1=Transforming growth factor beta-1.
TARGET CANDIDATE
DISCOVERY/
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
Latent
Myostatin
SPINAL MUSCULAR ATROPHY
Apitegromab
CARDIOMETABOLIC DISORDERS
Apitegromab in Obesity*
SRK-439 (novel anti-myostatin antibody)
Latent
TGF&#x3B2;-1
IMMUNO-ONCOLOGY
SRK-181 (selective context-independent,
anti-latent TGF&#x3B2;-1)
FIBROSIS
Selective context-dependent
(LTBP1 &amp; LTBP3) anti-latent TGF&#x3B2;-1
RGMc ANEMIA
Selective anti-RGMc
Undisclosed NEUROMUSCULAR DISORDERS </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g013.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Ph 3 SAPPHIRE in SMA
Apitegromab
additional neuromuscular
populations
EMBRAZE PoC in obesity
Advance SRK-439 to IND
Established PoC in ccRCC
End of Ph 1 meeting
Advance LTBP to IND
Nonclinical studies in renal
and pulmonary fibrosis
High Value Growth Opportunities
13
Neuromuscular
Disorders
Cardiometabolic
Disorders Immuno-Oncology Fibrosis
Strong Proprietary Platform </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g014.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Evolving into a Fully Integrated Biopharma Company
A G E N D A
Building a muscle-targeted franchise
The road ahead &#x2013; value drivers
Leveraging our proprietary platform
14</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g015.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Distinct &amp; High Value Opportunities for Myostatin Inhibition
15
Selective
Myostatin Inhibition
Apitegromab
SRK-439
Therapeutic Area Current Market Size
1 Revenue as of Biogen 4Q23 financial update, Roche 4Q23 financial update, and Novartis 4Q23 financial update
2 Morgan Stanley Research, &#x201C;Obesity Medication, Ripple Effects.&#x201D; April 14, 2024
~$20B2
Obesity
Projected to reach $100B by 20302
Ideal for Partnership
Spinal Muscular Atrophy
$4.5B1
SRRK Commercialization</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g016.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Global Rights Across
the Portfolio
29 patent families pending
Exclusivity through 2036
to 2043 for key assets
Novel Scientific Platform
Robust Pipeline
across 5 therapeutic areas
3 clinical programs
Multiple preclinical programs
Established Markets with
High Unmet Need
Apitegromab in SMA
SRK-439 in Obesity
SRK-181 in Immuno-oncology
Experienced Team
~150+ Employees
~74% R&amp;D
Deep rare disease, R&amp;D,
FDA/EMA approval experience
Powerful Building Blocks
16
Leveraging Our Building Blocks, Transformative 18 Months Ahead
* Subject to regulatory approval </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g017.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Phase 3 SAPPHIRE Trial
Proof of Concept
in Obesity
Significant Inflection Points
in Next Year
Preparing to Launch SMA
in US and EU*
Global Rights Across
the Portfolio
29 patent families pending
Exclusivity through 2036
to 2043 for key assets
Novel Scientific Platform
Robust Pipeline
across 5 therapeutic areas
3 clinical programs
Multiple preclinical programs
Established Markets with
High Unmet Need
Apitegromab in SMA
SRK-439 in Obesity
SRK-181 in Immuno-oncology
Experienced Team
~150+ Employees
~74% R&amp;D
Deep rare disease, R&amp;D,
FDA/EMA approval experience
Value Drivers
Powerful Building Blocks
17
Phased approach
to building key capabilities
Well established presence
within SMA Community
Leveraging Our Building Blocks, Transformative 18 Months Ahead
* Subject to regulatory approval </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g018.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Evolving into a Fully Integrated Biopharma Company
A G E N D A
Building a muscle-targeted franchise
The road ahead &#x2013; value drivers
Leveraging our proprietary platform
18</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g019.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Near-Term 2024 &amp; 2025 Anticipated Milestones
19
Milestones 2024 2025
SRK-181 data at ASCO
&#x2022; Oral presentation June 3
&#x2022; Developmental Therapeutics-Immunotherapy
SRK-439 data at American Diabetes Association
&#x2022; Oral presentation June 23
&#x2022; New Insights into Therapeutic Strategies for Obesity and Diabetes
EMBRAZE Ph 2a Trial (apitegromab in obesity)
&#x2022; Trial open for enrollment
&#x2022; Topline data expected mid-2025
SAPPHIRE Ph 3 Trial (apitegromab in SMA)
&#x2022; Topline readout in Q4 2024
Potential SMA launch in Q4 2025, if successful &amp; approved
Study in SMA Patients &lt; 2 Years of Age
&#x2022; Study design endorsed by EMA&#x2019;s paediatric committee
&#x2022; Study initiation planned for 2025 </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g020.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Strategic Roadmap: Our Vision for 2030
20
Multi-Billion Dollar Global Neuromuscular
Franchise
Established in key major markets
5 Clinical Programs
Including additional neuromuscular assets
Multiple Research Programs
Across TGF&#x3B2; superfamily of growth
factors
New Targets
Leveraging our world-leading antibody
engineering capabilities to pursue targets
beyond TGF&#x3B2; superfamily
Scholar Rock
2030
Scholar Rock
Today
Building Commercial
Preparedness in US &amp; EU
3 Clinical Programs
Multiple Research
Programs</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g021.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
From a World-Class Scientific Platform to a World-Class
Biopharma Company
21
I N S U M M A R Y
PLATFORM
PIPELINE
PEOPLE
Unparalleled selectivity to
optimize efficacy and safety
Broad opportunities to improve
patient outcomes in areas of
high unmet need
Seasoned research,
development and commercial
teams
Industry-leading anti-myostatin
portfolio
SMA &amp; Obesity represent significant
revenue opportunity </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g022.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab:
Development Program
Jing Marantz
Chief Medical Officer
22</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g023.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Upcoming Catalyst: Topline Data Expected in Q4 2024
23
A P I T E G R O M A B D E V E L O P M E N T P R O G R A M
Where We Were
Phase 2
Where We Are
Phase 3
12-Month
COMPLETE COMPLETE
12-Month
IN PROCESS
Future
48-Month EXTENSION
Long-Term
EXTENSION
&#x2022; Q4 2024 data1
&#x2022; 2025 launch2
1 Anticipated
2 Subject to regulatory approval </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g024.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab for SMA Development Program
A G E N D A
24
Evidence supporting apitegromab&#x2019;s potential
Pivotal SAPPHIRE trial: Why we are confident
Where we plan to go</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g025.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
25
Why We Are Confident
A P I T E G R O M A B F O R S P I N A L M U S C U L A R A T R O P H Y
Selective muscle-targeting designed to
improve motor function
while minimizing
off-target effects
&gt;90% patient
retention,1 well
tolerated profile supports
durability of treatment
1. Muscle Targeting 4. TOPAZ
Safety Profile
Trial design informed by
insights from TOPAZ
3. SAPPHIRE
Optimized for Success
TOPAZ clinical
proof-of-concept with
substantial and durable
effect across broad SMA
patients ages 2-21
2. Clinical
Proof-Of-Concept
1 Based on TOPAZ patients receiving combination therapy after 4 years of treatment. Data cutoff date: April 2024</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g026.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
* Based on Animal Model Data; 1. Long KK, et al. Hum Mol Genet. 2019;28(7):1077-1088; 2. Pirruccello-Straub M, et al. Sci Reports. 2018;8(1):2292. doi:10.1038/s41598-018-20524-9 3. Figure 26
adapted from: SMA Foundation Overview. http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.; Accessed April 18, 2021. For illustrative purposes only
Motor neuron
degeneration3
Apitegromab
Muscle fiber
atrophy
Selectively Targets Muscle to Address Unmet Needs
# 1 S E L E C T I V E M U S C L E T A R G E T I N G
Apitegromab is a selective
MUSCLE-TARGETED APPROACH
designed to improve motor function*
1,2
Myostatin is a negative
modulator of muscle growth
Evidence indicates upstream
targeting of structurally
differentiated pro- and latent
myostatin minimizes undesirable
off-target effects
Myostatin
Apitegromab</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g027.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
0.6
1.3
2.3 2.4
0
1
2
3
4
Baseline 6 months 12 months 24 months 36 months
27
Motor Function Improvements Were Substantial &amp; Sustained Over 36 Months
n= 35 29 32 29 28
95% CI= (1.4, 4.1) (1.2, 6.0) (1.9, 6.6) (1.0, 6.9)
Pooled Nonambulatory Patients
Age 2-21 Years
All Doses (N=35)
2.8
3.6
4.2 4.0
0
1
2
3
4
5
6
7
Baseline 6 months 12 months 24 months 36 months
For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population included patients
receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). This analysis excludes data post scoliosis surgery from seven patients. One patient did
not conduct HFMSE at time of database lock for 24 months, however, this patient had an unscheduled HFMSE score one month prior to their scheduled visit. In the most recent analysis, this result was included in the 24-month analysis. Error bars
represent SE. CI represents confidence interval. SMN Rx=SMN therapy. In the age 2-21 group, 18/28 patients achieved &#x2265; 1-pt gains, and 11/28 patients &#x2265; 3-pt gains at 36 months. Data cutoff date as of March 13, 2023. Apitegromab is an
investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been
established.
# 2 P H A S E 2 T O P A Z C L I N I C A L P R O O F - O F - C O N C E P T
Mean Change from Baseline (+SE)
Age 2-21 Years
All Doses (N=35)
n= 35 28 31 31 27
95% CI= (-0.2, 1.4) (0.2, 2.3) (1.2, 3.3) (1.1, 3.7)
HFMSE RULM
Baseline mean age=7.3 | Time on SMN Rx=24.1m Baseline mean age=7.3 | Time on SMN Rx=24.1m
Mean Change from Baseline (+SE)</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g028.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
28
SAPPHIRE Phase 3 Design is Optimized by Insights from TOPAZ
# 3 P H A S E 3 S A P P H I R E T R I A L O P T I M I Z E D F O R S U C C E S S
TOPAZ Learnings
HFMSE=Hammersmith Functional Motor Scale Expanded.
*Nonambulatory is defined as unable to independently ambulate without aids or orthotics over 10 steps at time of walk test during screening.
SAPPHIRE Trial Design
Study
Population
Age
Duration
Dose
&#x2022; Substantial HFMSE gains in nonambulatory* patients
&#x2022; Type 2/3 SMA cohorts
&#x2022; Nonambulatory* Type 2/3 SMA patients
&#x2022; Primary efficacy endpoint: HFMSE
&#x2022; Exploratory age 2-12 analysis in nonambulatory
 Type 2/3 showed transformative potential
&#x2022; Age 2-12 main efficacy population
&#x2022; Age 13-21 exploratory population
&#x2022; HFMSE gains substantial by 12 months of treatment
&#x2022; Clear dose response with greater effect
observed with 20 mg/kg over 2 mg/kg
&#x2022; 12-month treatment duration
&#x2022; 20 mg/kg apitegromab dose
&#x2022; 10 mg/kg apitegromab dose </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g029.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
29
SAPPHIRE Trial Design - Calibrated and Targeted
# 3 P H A S E 3 S A P P H I R E T R I A L O P T I M I Z E D F O R S U C C E S S
Randomized, double-blind, placebo-controlled (enrolled n=188)
Enrolled patients receiving SMN-targeted therapy (nusinersen or risdiplam)
Completed enrollment in 3Q 2023
Apitegromab (20 mg/kg IV q4w)
Apitegromab (10 mg/kg IV q4w)
Placebo (IV q4w)
MAIN POPULATION
n=156
Ages 2-12
Nonambulatory Types 2/3 SMA
N=52
N=52
N=52
R
Exploratory Population
N = 32, Ages 13-21
2:1 apitegromab 20 mg/kg vs placebo
Stratification (across main and exploratory)
Age at SMN therapy initiation (age &lt; 5 vs age &#x2265; 5)
SMN-targeted therapy (nusinersen vs. risdiplam)
Endpoints
Primary Efficacy:
Mean HFMSE change from baseline at 12 months
Additional Efficacy Measures:
RULM, WHO, other outcome measures
Safety, PK/PD, ADA
Screening Treatment (52 weeks)
Nonambulatory is defined as unable to independently ambulate without aids or orthotics over 10 steps at time of walk test during screening</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g030.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
30
SAPPHIRE &#x2013; Clear Goals
# 3 P H A S E 3 S A P P H I R E T R I A L O P T I M I Z E D F O R S U C C E S S
Improved motor function (HFMSE1 and RULM) across broad
SMA patients ages 2-21 and regardless of type of SMN-targeted therapy
Improved caregiver-reported outcomes (PROMIS-Fatigue
and PEDI-CAT) consistent with motor function improvement
Safety and tolerability profile that supports long-term use
1 Primary efficacy endpoint of the SAPPHIRE trial
Study Aims to Demonstrate </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g031.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
31
Well Tolerated Safety Profile &amp; Low Discontinuation Rate
# 4 T O P A Z S A F E T Y P R O F I L E
RIGHT
TIME
Latent Form
Myostatin RIGHT
TARGET
&#x2022; &gt;90% of patients on combination therapy remain on study
after 4 years of treatment1
&#x2022; Consistent treatment-emergent adverse events (TEAEs) with
previous reports with no new findings after &gt;200 patient years of
exposure in SMA2
&#x2012; Most frequently reported TEAEs included headache, pyrexia,
COVID-19, nasopharyngitis, &amp; upper respiratory tract infection
&#x2012; TEAEs were mostly mild to moderate and generally consistent with
the underlying patient population and nusinersen therapy
&#x2022; No treatment-related serious AEs or hypersensitivity reactions
&#x2022; No report of positive anti-apitegromab antibodies (ADA)
1 Excludes patients on monotherapy
2 Data cutoff date: April 2024</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g032.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab for SMA Development Program
A G E N D A
32
Evidence supporting apitegromab&#x2019;s potential
Pivotal SAPPHIRE trial: Why we are confident
Where we plan to go</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g033.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Evidence from TOPAZ to Support Apitegromab&#x2019;s Potential in SMA
SMN therapies generally plateau after initial gains
Substantial HFMSE gains on top of SMN therapy
Motor function improvement showed dose response
and no clear correlation with nusinersen exposure
Caregiver-reported outcomes demonstrated
improved fatigue and daily activities
High patient retention on study
33
1
2
3
4
5</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g034.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
-2
-1
0
1
2
3
4
Unmet Need to Address Muscle Atrophy
34
Overall population age 2-25
Change in HFMSE* Over Four Years with Risdiplam2
Risdiplam n= 120 120 119 117 109 106 89 99 101 97
Placebo n= 60 60 58 58
Risdiplam Placebo (months 0-12)
Mean (+/-SE) Change in HFMSE
Total Score From Baseline*
Visit, months
0 6 12 18 24 30 36 42 48
Change in HFMSE Over Four Years with Nusinersen1
Overall population age 2-12
Nusinersen n= 84 82 84 84 83 76 83 83 79 61 20
Placebo n= 42 41 41 42 42 39
1 Mercuri E, et al. Presented at: World Muscle Society Congress 2020, P. 257
2 Oskoui M, et al. Presented at: 2021 Muscular Dystrophy Association Clinical &amp; Scientific Conference; March 15-18, 2021. Poster 80.
HFMSE, Hammersmith Functional Motor Scale&#x2013;Expanded; SE, standard error.
*MFM was primary efficacy endpoint of SUNFISH. HFMSE was a secondary endpoint. This third-party information is provided for
background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.
# 1 S M N T H E R A P I E S : H F M S E S C O R E S G E N E R A L L Y P L A T E A U A F T E R I N I T I A L G A I N S Mean (+SE) Change in HFMSE Total Score From Baseline
Initial
Treatment
CHERISH
Chronic Maintenance Phase
SHINE
-4
-2
0
2
4
6
8
1 92 169 253 350 450 690 930 1170 1410 1650
Nusinersen in CHERISH and SHINE Sham control in CHERISH
Analysis Visit, days</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g035.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
35
Motor Function Gains Were Substantial &amp; Sustained Over 36 Months
# 2 S U B S T A N T I A L H F M S E G A I N S W I T H A P I T E G R O M A B O N T O P O F S M N T H E R A P Y
n= 35 29 32 29 28
95% CI= (1.4, 4.1) (1.2, 6.0) (1.9, 6.6) (1.0, 6.9)
Age 2-21 Years
All Doses (N=35)
2.8
3.6
4.2 4.0
0
1
2
3
4
5
6
7
Baseline 6 months 12 months 24 months 36 months
HFMSE
Baseline mean age=7.3 | Time on SMN Rx=24.1m
Mean Change from Baseline (+SE)
&#x2022; Patients enrolled in the TOPAZ study had
received nusinersen for a mean of ~2 years,
well into the steady maintenance phase
&#x2022; HFMSE gain stands above outcomes
observed well into the plateau phase of
nusinersen treatment
For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given
timepoints. This analysis population included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to
20 mg/kg in Year 2). This analysis excludes data post scoliosis surgery from seven patients. One patient did not conduct HFMSE at time of database lock for 24 months, however, this patient
had an unscheduled HFMSE score one month prior to their scheduled visit. In the most recent analysis, this result was included in the 24-month analysis. Error bars represent SE. CI represents
confidence interval. SMN Rx=SMN therapy. In the age 2-21 group, 18/28 patients achieved &#x2265; 1-pt gains, and 11/28 patients &#x2265; 3-pt gains at 36 months. Data cutoff date as of March 13,
2023. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any
other health authority, and its safety and efficacy have not been established.</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g036.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Motor Function Improvement Mainly Attributable to Apitegromab
36
HFMSE, Hammersmith Functional Motor Scale Expanded.
Dose response graph: Crawford TO, et al. Neurology. 2024; 102 (5). Scatter plot of prior nusinersen treatment duration vs change in HFMSE from baseline,
a post-hoc analysis in nonambulatory. Types 2 and 3 participants in TOPAZ. Patients skipped 3 or more doses due to COVID-site restrictions excluded;.
Apitegromab is an investigational product candidate under development.
-5
0
5
10
15
20
0 4 8 12 16 20 24 28 32 36 40
Change in HFMSE from Baseline
Duration of Previous Nusinersen Exposure (Months)
# 3 H F M S E S H O W E D D O S E R E S P O N S E A N D N O C L E A R C O R R E L A T I O N W I T H D U R A T I O N O F P R I O R N U S I N E R S E N
&#x2022; Dose response observed in HFMSE in nonambulatory &#x2265;Age 2 group randomized to 2
mg/kg and 20 mg/kg in a double-blind fashion
&#x2022; Both arms showed early benefit with a greater latency of the low dose arm,
supporting that the effect is mainly attributable to apitegromab
&#x2022; Patients enrolled were already in the chronic maintenance phase of nusinersen
(mean prior exposure ~2 years) where motor function generally plateaus
&#x2022; Lack of clear correlation between 12-month HFMSE &amp; duration of prior nusinersen
exposure in patients aged 2 &#x2013; 21 suggests motor function improvement mainly
attributable to apitegromab
Lack of Correlation Suggests Improvement
Attributable to Apitegromab
Clear Benefit Attributable
to Apitegromab
0
2
4
6
8
Baseline 8 16 24 32 40 Month 12
endpoint Time (weeks)
Change from Baseline of
HFMSE Score
Apitegromab 2 mg/kg
Apitegromab 20 mg/kg
10
10
10
10
10
10
7
8
8
8
8
8
9
8
2 mg/kg
20 mg/kg
Apitegromab sample size at each visit</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g037.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
37
Time (weeks)
No. of observations
Time (weeks)
No. of observations IMPROVEMENT Change from baseline (
&#xB1;SE)
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
0 0 8 16 24 32 40 52 68 84 104 120 136 156
-2
-1
0
1
2
3
4
5
0 0 8 16 24 32 40 52 68 84 104 120 136 156
Year 1 Year 2 Year 3
31 29 30 21 23 25 25 27 22 23 16 15 17
IMPROVEMENT
N = 35; Baseline mean age=7.3 | Time on SMN Rx=24.1m Change from baseline (
&#xB1;SE)
Year 1 Year 2 Year 3
25 23 22 19 19 22 16 18 19 19 16 14 14
Caregivers Report Improved Self-Sufficiency and Fatigue
# 4 C A R E G I V E R - R E P O R T E D O U T C O M E S D E M O N S T R A T E D I M P R O V E D F A T I G U E A N D D A I L Y A C T I V I T I E S
PEDI-CAT Daily Activities
PROMIS Fatigue (Proxy)
Autonomy:
&#x201C;She is able to access a lot
of her world way more
than she was able to
[before the trial]."
Fine Motor Skills:
&#x201C;She can take lids off markers on
her own. She is able to use
crayons&#x2026;She can brush her own
teeth and dress Barbie.&#x201D;
Motor improvements:
&#x201C;&#x2026;since the trial she&#x2019;s been
able to go from lying down to
sitting on her own, to getting
into the sitting position.&#x201D;
Independence:
&#x201C;She has more recently gained
the ability to crawl. She can get
into the crawling position on her
own and move across the room,
and stand on her own&#x2026;&#x201D;
HFMSE=Hammersmith Functional Motor Scale Expanded; OC=observed case; PEDI-CAT=Pediatric Evaluation of Disability Inventory Computer Adaptive Test; PROMIS=Patient Reported Outcome Measurement
Information System; RULM=Revised upper limb module; SE=standard error of the mean. SMN Rx=SMN therapy. Data on File. Scholar Rock, Inc. Cambridge, MA. Data cutoff date as of March 13, 2023. The updated
PEDI-CAT analysis included additional records (2 at 12 months and 1 at 24 months) that were not available at the time of previous analysis. Apitegromab is an investigational drug candidate being evaluated for the
treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.
1 Pokrzywinski R et al. Presented at AAN, 2024.
2 Data on file, Scholar Rock, Inc. </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g038.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
&#x2022; 57 enrolled
&#x2022; 8 discontinued: 2 due to COVID-19 concerns; 1
due to work schedule, 5 on monotherapy due to
perceived lack of benefit
&#x2022; &gt;90% of patients on combination therapy remain
on study with 4 years of treatment1
&#x2022; 58 enrolled
&#x2022; 57 completed primary treatment period and
enrolled in the extension study
&#x2022; 1 withdrew consent
&gt;90 Percent of Patients on Combination Therapy Remain on Study
38
# 5 H I G H P A T I E N T R E T E N T I O N O N S T U D Y
Primary Treatment (12 Months) Extension Phase
TOPAZ Safety Profile
1Excludes patients on monotherapy. Data cutoff date: April 2024
*Nonambulatory is defined as unable to independently ambulate without aids or orthotics over 10 steps at time of walk test during screening.
~94% (33/35) of nonambulatory* patients remain on study with 4 years of treatment</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g039.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab for SMA Development Program
A G E N D A
39
Evidence supporting apitegromab&#x2019;s potential
Pivotal SAPPHIRE trial: Why we are confident
Where we plan to go</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g040.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Where We Plan to Go: Expanding to Benefit More People Living with SMA
*Pending approval
40
2024 2025
Q4 Data
Readout
&#x2022; BLA /MAA Filing
&#x2022; Regulatory Approval*
&#x2022; Study in SMA Patients &lt; 2 Years of Age
&#x2012; Study design endorsed by EMA&#x2019;s paediatric
committee
&#x2012; Study initiation planned for 2025
A P I T E G R O M A B D E V E L O P M E N T P R O G R A M</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g041.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Advancing a Novel Muscle-Targeted Therapy for SMA
41
I N S U M M A R Y
&#x2022; High confidence based on proof-of-concept data in SMA
&#x2022; Q4 pivotal readout with potential 2025
regulatory approval &amp; commercialization
&#x2022; Studies planned to support additional
indications for apitegromab</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g042.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab:
Commercial Readiness
Tracey Sacco
Chief Commercial Officer
42</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g043.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab: Commercial Readiness
A G E N D A
SMA market insights
Commercialization planning
43</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g044.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Our Purpose: Create Possibilities for Those Living with SMA
44
Muscle is everything. I want to
live knowing that I have the
strength to take care of myself
if left alone.
- Lyza</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g045.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Listening to the Customer Voice to Stay Focused on Our Purpose
45
Building Deep Insights
&#x2022; &gt;15 market research and insights projects with
US, EU, and UK participants
&#xF067; 250+ caregivers of or people living with SMA
&#xF067; 340+ HCPs, including both neurologists and
physical therapists
&#xF067; 60+ payer insights
&#x2022; Ongoing discussions with SMA patient advocacy
organizations and SMA treaters
Source: Scholar Rock Internal Research 2022-2024
HCP=Healthcare Professional </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g046.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SMA Has Evolved &#x2013; Today Patients are Diagnosed, Treated, and
Surviving Longer
&#x2022; Newborn screening leading to earlier
treatment
&#x2022; Broad and expanding global access to
treatment
&#x2022; Concentrated care in US and EU
&#x2022; Engaged and organized global patient
advocacy
46
SMA Has Evolved Cure SMA Care Center Network
Sources: https://www.curesma.org/sma-care-center-network accessed April 22, 2024; https://odysma.sma-europe.eu accessed April 22, 2024; Internal Scholar Rock market
research</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g047.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Patient Demand, HCP Feedback, and Payer Proactivity Suggest:
More is Still Needed
Sources: Cure SMA. Education on adult patient expectations according to copy number and disease status at time of report. September 2022. Internal
Scholar Rock market research; Managed Markets Insight &amp; Technology, LLC
*As measured by covered lives; coverage for SMA approved therapy following demonstrated decline post-treatment with SMA approved gene therapy 47
Patient Demand Physician Feedback Payer Proactivity
% of patients who identified
improvement in muscle
strength as what they seek
most from a new treatment in
SMA
% of US commercial lives
whose plan already covers
combination SMA therapy*
97%
% of SMA patients for
whom HCPs
would prescribe a muscle
targeted therapy
&gt;70% &#x2153;</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g048.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Progressive Muscle Weakness Remains a Core Unmet Need
48
Personal hygiene, using the toilet and the shower
on my own would be huge. My four-year-old can do
it on her own. It&#x2019;s degrading.
 &#x2013; US Patient
Patients treated with [nusinersen and risdiplam]
are receiving only modest benefit. We need to restore
motor function that enables practical improvement in
daily activities / independence.
 &#x2013; National MCO
Source: Internal Scholar Rock market research
HFMSE = Hammersmith Functional Motor Scale Extended; MCO = Managed Care Organization
Muscle atrophy and loss of strength is a key issue in
these patients. Increasing a patients&#x2019; HFMSE score is
really important. Its measurable and meaningful.
 &#x2013; Pediatric Neurologist (UK)</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g049.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
1. 2. 3. 4.
SMA is the Right Opportunity for Scholar Rock&#x2019;s First Launch
49
Clear Unmet Need Concentrated and
Proactive Care
Engaged Patient
Community
Payer
Receptivity
&#x2022; Patient, HCP, and
payer communities
recognize remaining
needs in SMA
&#x2022; Patients already
diagnosed and treated
proactively
&#x2022; High concentration of
care
&#x2022; Established value of
improving motor
function
&#x2022; Proactive advocacy,
patient, and caregiver
community
&#x2022; Aligned on need for
muscle targeted
therapy</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g050.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Apitegromab: Commercial Readiness
A G E N D A
SMA market insights
Commercialization planning
50</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g051.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Why We Are Confident About Potential Commercial Success of
Apitegromab
51
Gold standard efficacy measure in SMA
&#x2022; HFMSE is a SMA-specific, validated functional scale
&#x2022; Commonly used in practice by both HCPs and payers
Long-term treatment experience in SMA patients
&#x2022; SMA patients treated &gt;4 years on apitegromab1
&#x2022; High retention rate in TOPAZ
Fits into current SMA practice
&#x2022; Used with nusinersen or risdiplam
&#x2022; Monthly dosing
1 Ph 2 TOPAZ trial (apitegromab in SMA), data as of April 2024
HFMSE = Hammersmith Functional Motor Scale Extended</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g052.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SMA Represents a Significant Opportunity for Apitegromab
52
~$4.5B1
global revenue for three SMN
targeted therapies
Apitegromab global
revenue potential
&gt;$1.0B2

1
 Revenue as of Biogen 4Q23 financial update, Roche 4Q23 financial update, and Novartis 4Q23 financial update
2 Scholar Rock internal estimates as of May 2024
SMA=Spinal muscular atrophy; SMN=Survival motor neuron.</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g053.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Commercialization Approach: Three Key Elements
53
1. Engagement 2. Patient Experience 3. Execution
&#x2022; Partnering with SMA
communities
&#x2022; Ensure excellent patient
experience
&#x2022; Build team to deliver
US launch &amp; global
expansion
Commercialization Plan</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g054.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Partnering With the SMA Community
54
1 . E N G A G E M E N T
&#x2022; MSL team on the ground
&#x2022; Continued engagement with
US and EU patient advocacy
&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
MSL= Medical Science Liaison
&#x2022; Amplify patient voice with
muscle-focused education</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g055.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Secure Access and Customize Treatment to Meet Patient Needs
55
2 . P A T I E N T E X P E R I E N C E
Optimize
Treatment
Experience
Ensure
Access
Provide
Support
Vision for Patient Experience
Engage payers early and
focus on value demonstration
Design for maximum
flexibility to enable seamless
integration into practice
Customize patient services
to meet patient and HCP
needs throughout treatment
journey</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g056.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Building to Achieve Commercial Success
56
3 . E X E C U T I O N
Geographic Expansion
&#x2022; Commercialize in selected
European countries*
&#x2022; Remaining EU and ROW
expansion through
distributorships &amp;
partnerships
U.S. Launch*
&#x2022; Expand commercial
capabilities
&#x2022; Efficient US customer facing
footprint (30-50 FTEs)
Building the Foundation
&#x2022; Focused and experienced
team
&#x2022; Launch, rare disease, and
SMA experience
2024 2025 2026+
* Subject to regulatory approval
ROW= Rest of world</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g057.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Path to Achieving Commercial Success in SMA
57
I N S U M M A R Y
&#xF067; Clear unmet need and favorable market dynamics
&#xF067; Competitive and attractive potential profile
&#xF067; Engagement, patient-focus &amp; execution
The right market
The right medicine
The right plan
Apitegromab global
revenue potential
&gt;$1.0B1

1 Scholar Rock internal estimates as of May 2024</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g058.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: Selective
Anti-Myostatin Designed for
Optimal Profile in Obesity
Mo Qatanani
Chief Scientific Officer
58</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g059.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
A Differentiated Approach
A G E N D A
Different approaches to muscle preservation
SRK-439: novel asset, differentiated profile
59
Best-in-class platform for selectivity </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g060.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Differentiated Approach to Targeting Growth Factors
60
S E L E C T I V I T Y D R I V E S S U C C E S S
Transformational Medicines
Deep structural insights to validated targets
Industry-leading antibody design and protein engineering to
selectively target latent growth factors
Optimized for efficacy and avoids off-target effects
Advantages of Scholar Rock&#x2019;s Approach
Traditional Target
&#x201C;Mature&#x201D; active growth factor
Growth factor
Scholar Rock&#x2019;s Target
Latent growth factor
Precursor complex
Precursor complex
Highly selective
monoclonal
antibodies</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g061.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Platform and Expertise Drive Success in Clinic
61
Superb Engineering Clinic
SRK-439 IND in 2025
SRK-181
Anti-PD1 Anti-PD1/ SRK-181-mIgG1
T R A N S L A T I O N A L S U C C E S S T O T H E C L I N I C
Apitegromab
Muscle stimulation (Hz)
Muscle strength
(torque)
Translational Models
Treatment
Treatment</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g062.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
A Differentiated Approach
A G E N D A
Different approaches to muscle preservation
SRK-439: novel asset, differentiated profile
62
Best-in-class platform for selectivity </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g063.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Muscle is Critical for Overall Health
1. Aristizabal JC et al. Eur J Clin Nutr 2015; 2. Lindegaard B et al. J Clin Endocrinol Metab 2008; 3. Srikanthan P, Karlamangla AS J Clin Endocrinol Metab 2011; 4. Severinsen et al.
Endocr Rev. 2020; 5. Wewege MA, et al. Sport Med 2022; 6. Zurlo F. et al. J Clin Invest 1990; 7. Fukushima Y et al. Diabetes Metab J. 2016; 8. Roh E, Choi KM. Front. Endocrinol. 2020;
9. Volpi E, et al Curr Opin Clin Nutr Metab Care. 2004
63
Signal to other systems as an endocrine organ
impacting overall health4
Reduce visceral fat5
Increase bone density, strength, function, and longevity
and decreased risk of injury and disability7-9
Increase caloric expenditure post-exercise6
Enhance glucose homeostasis2 and better insulin
sensitivity and lower risk of prediabetes3
Increase basal metabolic rate (BMR)1
K E Y M E T A B O L I C O R G A N</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g064.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Advantages
Myostatin is the Right Target for Muscle Growth
Myostatin is specific to muscle1
Validated genetically with no evident safety liabilities 1-4
Inhibition leads to muscle growth in adults5
Selective targeting leads to improved motor function as seen in TOPAZ with favorable tolerability
profile observed in &gt;200 patient years of exposure in SMA 6

Pictures depict increase in muscle mass in myostatin null animals and humans
1. McPherron, A.C., et al. Nature 1997; 2. Schuelke, M., et al. NEJM 2004; 3. Kambadur, R., et al Genome Res. 1997; 4. Mosher, D.S., et al. PLoS 2007; 5. Abati E, et al. Cell Mol Life
Sci. 2022; 6. Ph 2 TOPAZ trial (apitegromab in SMA), data as of April 2024
64
I N D U C I N G M U S C L E G R O W T H</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g065.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Signaling receptor shared by
Myostatin, GDF-11 &amp; Activin A
Multiple Risks Associated with Non-Selective Targeting
1. Barrett et al., Adv Therapy 2021; 2. Crawford et al., Neurology 2024; 3. Garito T et al Clin Endocrinol 2018; 4. Amato AA et al Neurology 2021; 5. Heymsfield SB et al. JAMA 2021; 6. Vanhoutte F et
al. J Clin Pharmacol 2020; 7. Attie KM et al Muscle Nerve 2013; 8. Attie KM et al Am J Hematol 2014; 9. Campbell C et al. Muscle Nerve 2017; 10. Hoeper MM et al NEJM 2023; 11. Ruckle J et al, JBMR
2009; 12. Sherman ML et al J Clin Pharm 2013; 13. Muntoni F et al. Neurol Ther. 2024. 14. Rocco MD et al Nat Med 2023;
65
Promyostatin Pro-GDF-11 Proactivin
GDF-11 Activin A
ActRIIA/B
Apitegromab
SRK-439 Other Approaches
&#x2022; GI problems, e.g., diarrhea, pancreatitis 3-6
&#x2022; Nose bleeds (epistaxis), low platelet count,
telangiectasias7-10
&#x2022; Reduction in reproductive hormones in
males and females3, 7, 11, 12
&#x2022; Acne, rash, skin abscesses5, 13, 14
&#x2022; Madarosis (loss of eyebrows or eyelashes)14
Favorable
safety
 profile1,2
S E L E C T I V I T Y T O M Y O S T A T I N I S C R I T I C A L
Health Risks Observed with Non-Selective Inhibition of ActRII Pathway:
Myostatin</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g066.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
A Differentiated Approach
A G E N D A
Different approaches to muscle preservation
SRK-439: novel asset, differentiated profile
66
Best-in-class platform for selectivity </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g067.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Why We Are Confident in SRK-439
67
&#x2022; A new anti-myostatin
specifically suited for
obesity
&#x2022; Targets pro and latent
forms of myostatin
designed to minimize
undesirable off-target
effects
&#x2022; Preclinical data
demonstrated favorable
muscle mass
preservation and
metabolic effects
Scholar Rock&#x2019;s Unique
Approach Exquisite Selectivity Strong Scientific Validation </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g068.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: Differentiated Profile
68
Exquisite selectivity for myostatin
Potential for healthier weight loss in
combination with GLP-1 RA
Low efficacious dose and competitive profile
1
3
2</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g069.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439 Selectively Binds Latent Myostatin Scholar Rock&#x2019;s Target:
Latent Myostatin
SRK-439: Exquisite Selectivity for Myostatin
69
# 1 S E L E C T I V E F O R M Y O S T A T I N
&#x2022; Increasing SRK-439 concentrations lead to increased signal of binding
to myostatin with no signal observed for GDF-11 or Activin A
&#x201C;mature&#x201D; myostatin
Latent
myostatin Human Latent Myostatin
Human Latent GDF-11
Human Latent Activin A
0.001 0.01 0.1 1 10 100 1000
0.0
0.5
1.0
1.5
2.0
2.5
SRK-439 (nM)
Binding Intensity
(OD450)</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g070.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: Potential for Healthier Weight Loss Management in
Combination with GLP-1 RA
70
# 2 C O M B I N A T I O N G L P - 1 R A D A T A I N O B E S I T Y M O D E L S
&#x2022; Considerable lean mass loss with semaglutide
treatment
&#x2022; Combination with SRK-439 led to dose-dependent lean mass preservation
&#x2012; Effects seen with doses as low as 0.3 mg/kg
&#x2022; Dose dependent enhancement of fat mass
loss also observed, improving overall body
composition
Key Observations
-15
-10
-5
0
5
10
15 SRK-439 Maintains Lean Mass
Percent Change Lean Mass
from Baseline
0.1 0.3 1 3
Control + Sema
Control SRK-439
Treatment
&#x2731;
&#x2731;&#x2731;&#x2731;&#x2731;
SRK-439 (mg/kg) +
Semaglutide (0.04mg/kg)
p &lt; 0.05
p &lt; 0.0001
SRK-439 Maintained Lean Mass
in Semaglutide Treated Animals
Study conducted in Diet Induced Obesity (DIO) mouse model utilizing a murine chimera of SRK-439
GLP-1 RA: GLP1 receptor agonist</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g071.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
0
50
100
150
200
250
SRK-439 Further Improvement in Fasting Glucose in SemaglutideTreated Animals
Fasting Glucose (mg/dL)
0.1 0.3 1 3
Control + Sema
Control SRK-439
Treatment
&#x2731;
&#x2731;
&#x2731;
SRK-439: Further Improvement of Metabolic Health
71
# 2 C O M B I N A T I O N G L P - 1 R A D A T A I N O B E S I T Y M O D E L S
Key Observations SRK-439 Further Improved Fasting Glucose
in Semaglutide Treated Animals
&#x2022; Semaglutide reduced fasting glucose levels
as expected
&#x2022; Combination with SRK-439 led to further
improvement in fasting glucose levels by
~20% in a dose-dependent manner
&#x2022; Highlights the role of muscle preservation in
improving long term metabolic profile
SRK-439 (mg/kg) +
Semaglutide (0.04mg/kg)
p &lt; 0.05
p &lt; 0.05
p &lt; 0.05
Study conducted in Diet Induced Obesity (DIO) mouse model utilizing a murine chimera of SRK-439</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g072.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Are We Limiting Efficacy with Selective Targeting of Myostatin?
72
S E L E C T I V I T Y T O M Y O S T A T I N I S C R I T I C A L
Signaling receptor shared by
Myostatin, GDF-11 &amp; Activin A
Promyostatin Pro-GDF-11 Proactivin
GDF-11 Activin A
ActRIIA/B
Apitegromab
SRK-439 Other Approaches
Myostatin</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g073.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: More Potent than Anti-ActRII Antibody at
Maintaining Lean Mass
73
# 3 L O W E F F I C A C I O U S D O S E A N D C O M P E T I T I V E P R O F I L E
Head-to-Head Comparison to Non-Selective Myostatin
Inhibitor in DIO Mouse Model
-20
-15
-10
-5
0
Percent Change Lean Mass
from Baseline
&#x2731; &#x2731;
&#x2731;&#x2731;&#x2731;&#x2731;
&#x2731;&#x2731;&#x2731;&#x2731;
&#x2731;&#x2731;&#x2731;&#x2731;
&#x2731;&#x2731;&#x2731;&#x2731;
0.3 1 3 10 0.3 1 3 20
Antibody Treatment (mg/kg) +
Semaglutide (0.04mg/kg)
SRK-439 Anti-ActRII*
p &lt; 0.01
p &lt; 0.0001
p &lt; 0.0001
p &lt; 0.0001
p &lt; 0.0001
&#x2022;SRK-439 preserved GLP-1 driven lean
mass loss dose-dependently and at lower
doses than anti-ActRII
&#x2022;Highlights efficacy of SRK-439 and avoids
potential liabilities of non-selective
approach
&#x2022;Low target dose of SRK-439 supports
subcutaneous profile
Key Observations
*Murine chimera of Bimagrumab
Study conducted in Diet Induced Obesity (DIO) mouse model utilizing a murine chimera of SRK-439 </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g074.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: Best in Class Potential
74
SRK-439 ActRII Ab Ligand Trap Adnectin
Selectivity for myostatin
Action limited to muscle
Combination GLP-1 RA data in obesity
preclinical models1-3
Low efficacious dose in preclinical
obesity models1-3
Lower risk of potential undesirable
effects in clinic4
X
X
X
X X
X
X
X
X X X
X
GLP-1 RA: GLP1 receptor agonist
1. Nunn E, et al., Mol Metab 2024; 2. Schang G., et al, J. Endoc Soc 2023; 3. Ackerman, P, et al. Obesity Week 2023 Poster 211;
4. See also references on slide titled, &#x201C;Multiple Risks Associated with Non-Selective Targeting&#x201D; in this presentation. </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g075.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
SRK-439: The Right Molecule for Healthy Weight Loss
75
I N S U M M A R Y
&#xF067; Highly selective approach
&#xF067; Targets muscle
&#xF067; Efficacy without potential liabilities of non-selective approaches
&#xF067; Designed for subcutaneous low frequency dosing with
robust subcutaneous exposure and long half life
The right target
The right tissue
The right safety profile
The right product profile</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g076.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Cardiometabolic
Development Program
Aiming for Healthier Weight Loss
Jing Marantz
Chief Medical Officer
76</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g077.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Cardiometabolic Development Program
A G E N D A
Overview of muscle-targeted opportunity
SRK-439 Development Pathway
77</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g078.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Significant Proportion of Weight Loss Due to Loss of Lean Muscle Mass
78
L O S S O F L E A N M U S C L E S I G N I F I C A N T W I T H G L P - 1 A G O N I S T T H E R A P Y

GLP-1 Agonist=Glucagon-like peptide-1 receptor agonist
1. Muller TD, et al Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022; 21, 201&#x2013;223;
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002;
3. Jastreboff AM, et al Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022; 387 (3): 205-216;
Current weight loss strategies
challenged by:
Tolerability
Significant muscle loss1-3
Lack of durability
Lean
muscle
loss</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g079.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Lean Muscle Is Essential to Healthy Metabolic Function
79
L O S S O F L E A N M U S C L E S I G N I F I C A N T W I T H G L P - 1 A G O N I S T T H E R A P Y
GLP-1 Agonist=Glucagon-like peptide-1 receptor agonist
1. Aristizabal JC, Freidenreich DJ, Volk BM, et al. Effect of resistance training on resting metabolic rate and its estimation by a dual-energy X-ray absorptiometry metabolic map. Eur J Clin Nutr.2015; 69, 831&#x2013;836.
https://doi.org/10.1038/ejcn.2014.216; 2. Lindegaard B, Hansen T, Hvid T, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with
lipodystrophy. J Clin Endocrinol Metab. 2008; 93:3860&#x2013;9; 3. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and
Nutrition Examination Survey. J Clin Endocrinol Metab. 2011; 96:2898&#x2013;903. doi: 10.1210/jc.2011-0435; 4. Wewege MA, Desai I, Honey C, et al. The effect of resistance training in healthy adults on Body fat percentage, fat mass
and visceral fat: A systematic review and meta-analysis. Sports Med. 2022(Feb);52(2):287-300. doi: 10.1007/s40279-021-01562-2; 5. Zurlo, F., Larson, K., Bogardus, C., et al. Skeletal muscle metabolism is a major determinant
of resting energy expenditure. J Clin Invest. 1990;86(5), 1423-1427; 6. Fukushima Y, Kurose S, Shinno H, et al. Importance of lean muscle maintenance to improve insulin resistance by body weight reduction in female patients
with obesity. Diabetes Metab J. 2016;40: 147-153; 7. Roh E, Choi KM. Health consequences of sarcopenic obesity: a narrative review. Front. Endocrinol. 2020;11: 332; 8. Volpi E, Nazemi R, Fujita S. Muscle tissue changes with
aging. Curr Opin Clin Nutr Metab Care. 2004;7(4): 405-410.
Better insulin sensitivity and lower risk of prediabetes3
Reduced visceral fat4
Increased bone density, strength, function, longevity, and decreased
risk of injury and disability6-8
Increased caloric expenditure post-exercise5
Enhanced glucose homeostasis2
Increased basal metabolic rate1</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g080.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Potential Benefits
Our Solution Delivers Attractive Clinical Risk/Benefit Profile
80
&#x2022; Inhibition of myostatin, a negative regulator of muscle,
is known to promote muscle growth and function
&#x2022; Apitegromab, a selective myostatin inhibitor, has been shown
in a Phase 2 Proof-of-Concept study to improve motor
function
&#x2022; Preserving muscle, an endocrine organ with important role in
energy metabolism, has the potential to improve durability
of weight loss
&#x2022; Selective targeting minimizes off-target effects, potentially
supporting long-term use for healthy weight management
T H E R A P E U T I C P O T E N T I A L O F O U R M U S C L E - T A R G E T E D A P P R O A C H I N O B E S I T Y
Preserving muscle
Improving function
Improving durability
Long-term safety
Key Points</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g081.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Cardiometabolic Development Program
81
Overview of muscle-targeted opportunity
SRK-439 Development Pathway
A G E N D A</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g082.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
82
Apitegromab in SMA Improved Motor Function from Baseline
C A R D I O M E T A B O L I C D E V E L O P M E N T P R O G R A M
n= 35 29 32 29 28
95% CI= (1.4, 4.1) (1.2, 6.0) (1.9, 6.6) (1.0, 6.9)
Age 2-21 Years
Pooled Nonambulatory Patients (N=35)
2.8
3.6
4.2 4.0
0
1
2
3
4
5
6
7
Baseline 6 months 12 months 24 months 36 months
HFMSE Gain
Baseline mean age=7.3 | Time on SMN Rx=24.1m
Mean Change from Baseline (+SE)
0
2
4
6
8
Baseline 8 16 24 32 40 Month 12
endpoint Time (weeks)
Change from Baseline of
HFMSE Score
Apitegromab 2 mg/kg
Apitegromab 20 mg/kg
10
10
10
10
10
10
7
8
8
8
8
8
9
8
2 mg/kg
20 mg/kg
Apitegromab sample size at each visit
Dose Response in HFMSE
TOPAZ nonambulatory Cohort 3 patients randomized
to 2 mg/kg and 20 mg/kg in a double-blind fashion
HFMSE, Hammersmith Functional Motor Scale Expanded.
Dose response graph: Crawford TO, et al. Neurology. 2024; 102:e209151
Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g083.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Leveraging Apitegromab POC Study to Inform SRK-439 Development
83
C A R D I O M E T A B O L I C D E V E L O P M E N T P R O G R A M
Tests hypothesis of
selective anti-myostatin
in obese population
POC study
start*
POC data
readout*
Ph 2 proof-of-concept trial
APITEGROMAB + GLP-1 Agonist
2024 2025
SAPPHIRE
Topline Q4*
Potential
Commercial Launch*
APITEGROMAB SMA
Spinal Muscular
Atrophy
IND*
SRK-439 + GLP-1 Agonist
Novel asset for cardiometabolic
indication Phase 1 trial
Cardiometabolic
Disorders
Expected timelines
POC = Proof of Concept</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g084.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
84
Effect of apitegromab to preserve lean mass in obese or
overweight patients receiving a GLP-1 agonist
Safety and tolerability data to provide initial support for
long-term chronic use
Explore the potential effect of apitegromab to improve
metabolic profile and physical function
EMBRAZE Proof-of-Concept Study
C A R D I O M E T A B O L I C D E V E L O P M E N T P R O G R A M
Insights gained
from EMBRAZE study
to inform SRK-439
development
Study Aims to Demonstrate </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g085.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Launching Phase 2 Proof-of-Concept Study of Apitegromab in Obesity
85
E M B R A Z E T R I A L D E S I G N
Randomized, double-blind, placebo-controlled (n=100)
Enrolling patients who are overweight or obese
Enrollment expected to start in 2Q 2024
Screening (Up to 4 weeks)
&#x2022; Male or female, age &#x2265;18 and &#x2264;65 years old at the
time of informed consent
&#x2022; Stable body weight within 90 days of Screening
&#x2022; BMI &#x2265;30.0 kg/m2 to &#x2264;45.0 kg/m2 or &#x2265;27.0 kg/m2
to &lt;30.0 kg/m2 with the presence of 1 or more
weight-related comorbid condition(s)
ENDPOINTS
Primary Endpoint (Week 24)
Change from baseline in lean mass by DEXA scan
Secondary Endpoints
Additional weight loss measures, safety &amp; tolerability, PK/PD
Treatment (24 weeks)
Apitegromab Q4W + tirzepatide or semaglutide* QW
Placebo Q4W + tirzepatide or semaglutide* QW
ADDITIONAL
Exploratory Endpoints (Week 24 and 32)
Cardiometabolic profile (e.g., HbA1c), body
composition, physical function
R
N=50
N=50
8 weeks
(24 weeks)
Primary endpoint
(32 weeks)
Exploratory endpoints
*Participating patient will be assigned to either tirzepatide or semaglutide depending on availability.
Apitegromab dose regimen will be 10 mg/kg Q4W, based on projected exposure in the obese population comparable to that of 20 mg/kg Q4W in SMA
Tirzepatide and semaglutide dose regimen will follow the United States Prescribing Information.</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g086.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
FDA Guidelines Added Clinical Benefit
86
Regulatory Pathway
C A R D I O M E T A B O L I C D E V E L O P M E N T P R O G R A M
*Clinical Outcome Assessment: Frequently Asked Questions: https://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions#Consideration1
A clinical outcome assessment is a
measure that describes or reflects how
a patient feels, functions, or survives.*
Incremental Clinical Benefit
Incremental Weight Loss
&#x2022; Current weight management drugs approved based on total
body weight loss
&#x2022; Incremental weight loss as primary endpoint &#x2013; preservation of
lean mass may lead to additional weight loss incremental to
that mediated by GLP-1 agonist
&#x2022; Increased muscle mass has the potential to improve metabolic
profile (e.g., HbA1c)
&#x2022; Preserving lean body mass is expected to improve physical
function
&#x2022; FDA guidance supports combination strategy
&#x2022; Need to demonstrate the added clinical
benefit of the combination </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g087.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Platform and Expertise Drive Success in Clinic
87
T R A N S L A T I O N A L S U C C E S S T O T H E C L I N I C
Apitegromab
SRK-181
SRK-439
Anti-PD1 Anti-PD1/ SRK-181-mIgG1
Muscle stimulation (Hz)
Muscle
strength
(torque)
Differentiated Engineering Translational Models Clinic
IND in 2025</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g088.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
88
Cardiometabolic Program Has Key Ingredients For Success
I N S U M M A R Y : A D I F F E R E N T I A T E D A P P R O A C H
Regulatory Path Forward
FDA guidance supports combination
 strategy; SRK-439 development
 has the potential to improve
 function &amp; incremental weight loss
Leverages Apitegromab Study
First and only anti-myostatin to
 show clinical proof of concept,
 apitegromab&#x2019;s study in obesity
 informs SRK-439 development
SRK-439 Designed for Obesity
Specificity minimizes off-target
 effects; effect in translational models
 on preservation of lean mass, enhanced
 fat loss, &amp; improved metabolic profile
SRK-439
IND in 2025</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g089.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Closing Remarks
89
Jay Backstrom
President &amp; Chief Executive Officer</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="../../../cdn.kscope.io/d3f58c5077b1eb8582342386e30552b5-srrk-20240517xex99d2g090.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">&#xA9; 2024 Scholar Rock, Inc. All rights reserved.
Selectivity is
the Key
The hallmark of our
differentiated platform is
unparalleled selectivity
1
Large Unmet Needs
SMA and obesity represent high
value markets offering significant
potential revenue opportunities
2
Positioned
for Success
Experienced team executing
on strategy and goals
3
Advancing Our Journey Towards Commercialization
90
I N S U M M A R Y
Next 12 &#x2013; 24 months of execution is
expected to be transformative for our
company</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:avoid;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div></div></div></body></html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/10196\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
